Ascendis Pharma AS (ASND) Cotización

ASND new 52=week high

ASND new 52 week high

What goes down, must go up :)
Hope you banked, monk.

ASND new 52 week high

ASND new 52 week high

ASND 161 shares traded in pre-mkt. Take your profits- nobody going to hold up this dilution candidate.
Bearish

ASND After just one day of wooing, ASND is FALLING ...........in love with my short.
Irresistible attraction: fourteen-month delay on average, need for more money and a red market with housing assuring further rate increase.
Quote as of 5/02/2023 2:44PM ET
$86.375 -$0.365 (-0.421%)
Bearish
https://www.bing.com/videos/search?q=you+tube+music+roy+orbison+i%27m+falling&view=detail&mid=17436B40AE02F042D00317436B40AE02F042D003&FORM=VIRE

$ASND
A complete response letter (CRL) from the FDA delays a product’s entry to the market by an average of 14 months. Companies that receive the letters take an average of seven months just to respond to them.
FDA NEWS
Bearish

ASND Net Income -$622,419,000 in 2022

Anyone want to venture a guess when the raise will come?

I'll take a WAG and say within two weeks.

ASND Quote as of 5/02/2023 10:14AM ET

$88.07 +$1.33 (+1.533%)

I'm down -3.22% on my short. Did not choose well- 100% owned by institutions.. not easily budged.
I am counting on red days, 3 day rule, CRL and outside chance of a raise- it's all I got, lol

https://stockcharts.com/h-sc/ui?s=ASND

Short today at 85.34

How long will this languish before possible good news?

Will need to raise more $$

Ascendis Pharma: FDA Approves Skytrofa to Treat Pediatric Growth Hormone Deficiency > ASND
3:46 pm ET August 25, 2021

By Stephen Nakrosis

Ascendis Pharma A/S on Wednesday said the U.S. Food and Drug Administration approved its Skytrofa as a treatment for Pediatric Growth Hormone Deficiency.

The company said Skytrofa, or lonapegsomatropin-tcgd, is the first once-weekly treatment approved to treat Pediatric Growth Hormone Deficiency.

The company also said Skytrofa was approved to treat "pediatric patients one year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone."

The company said the approval includes its Skytrofa Auto-Injector and cartridges, which enable families to store the medicine at room temperature for up to six months.

The company said availability of Skytrofa in the U.S. is expected soon.

Ascendis said it would hold an investor conference call at 4:30 p.m. ET today.


Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

ASCENDIS PHARMA A/S is a Danish-based biopharmaceutical company, which is involved in manufacture products for rare diseases. The Company utilizes its TransCon technologies for treatment, which can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs. The Company is headquartered in Copenhagen, Denmark with offices in Heidelberg, Germany and Palo Alto, California.